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Background: Iron deficiency is a common nutritional deficiency amongst women of childbearing age. Peri-partum
iron deficiency anaemia (IDA) is associated with significant maternal, fetal and infant morbidity. Current options for
treatment are limited: these include oral iron supplementation, which can be ineffective and poorly tolerated, and
red blood cell transfusions, which carry an inherent risk and should be avoided. Ferric carboxymaltose is a new
treatment option that may be better tolerated.
The study was designed to assess the safety and efficacy of iron deficiency anaemia (IDA) correction with
intravenous ferric carboxymaltose in pregnant women with mild, moderate and severe anaemia in the second and
third trimester.
Methods: Prospective observational study; 65 anaemic pregnant women received ferric carboxymaltose up to
15 mg/kg between 24 and 40 weeks of pregnancy (median 35 weeks gestational age, SD 3.6). Treatment
effectiveness was assessed by repeat haemoglobin (Hb) measurements and patient report of well-being in the
postpartum period. Safety was assessed by analysis of adverse drug reactions and fetal heart rate monitoring during
the infusion.
Results: Intravenous ferric carboxymaltose infusion significantly increased Hb values (p < 0.01) above baseline levels
in all women. Increased Hb values were observed at 3 and 6 weeks post infusion and up to 8 weeks post-infusion.
Ferritin values increased significantly after the infusion. Only 4 women had repeat ferritin values post-partum which
remained above baseline levels. Fetal heart rate monitoring did not indicate a drug related negative impact on the
fetus. Of the 29 (44.6%) women interviewed, 19 (65.5%) women reported an improvement in their well-being and 9
(31%) felt no different after the infusion. None of the women felt worse. No serious adverse effects were found and
minor side effects occurred in 13 (20%) patients.
Conclusions: Our prospective data is consistent with existing observational reports of the safe and effective use of
ferric carboxymaltose in the treatment of iron deficiency anaemia in pregnancy.
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Iron deficiency is recognized as a common nutritional de-
ficiency amongst women of childbearing age in both the
developed and developing world [1]. Peri-partum iron de-
ficiency anaemia (IDA) is associated with significant ma-
ternal, fetal and infant morbidity. Poor outcomes for the* Correspondence: bernd.froessler@health.sa.gov.au
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striction, intrauterine fetal death, low Apgar scores and in-
fection [2]. Women with iron deficiency are also at risk of
adverse effects requiring medical interventions such as red
blood transfusion [3], cardiovascular problems, reduced
physical and cognitive performance, reduced immune
function, tiredness and increased depressive episodes [4].
Peri-partum maternal iron deficiency has also been associ-
ated with childhood developmental problems [5] and
negative mother-infant interactions such as an increase in
negative statements and decreased responsiveness [6].al Ltd. This is an Open Access article distributed under the terms of the Creative
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aemia (IDA) in pregnancy is common, due to the in-
creased demand for iron during pregnancy, required to
support maternal haemoglobin mass expansion, as well as
the growing fetus and placenta [7]. This is further aggra-
vated by blood loss associated with delivery. Deliveries by
both caesarean section and vaginal deliveries that require
instrumentation/intervention represent an even greater
risk [4] increasing a woman’s vulnerability for peri-partum
blood transfusion [3], chronic iron deficiency anaemia and
iron store depletion, all compromising maternal well-
being. However, this recognition has not resulted in a uni-
versal approach of iron supplementation [8].
Iron deficiency is potentially both preventable and
treatable. Effective management strategies that allow
women to replenish iron stores, both antenatal or during
labour, restore haemoglobin values and are likely to en-
hance the health of the mother and infant [9]. For many
decades the mainstay treatment of IDA has been oral
iron and red blood cell (RBC) transfusions. However,
oral iron supplementation can lead to significant side ef-
fects resulting in non-compliance in many patients [10]
and the risks for RBC transfusion are well described and
should be avoided whenever possible [11]. Intravenous
iron formulations offer an alternative approach in the
presence of moderate or severe anaemia, intolerance of
or non-adherence to oral iron and malabsorption states
[12]. Intravenous iron is less commonly used as fear of
anaphylaxis with iron dextran formulations, and long in-
fusion time with iron polymaltose, have led to reluctance
amongst clinicians [13]. The development of dextran
free parenteral iron formulations with an improved
safety profile, and a more rapid delivery time suggests
that intravenous iron should be considered as a mainstay
treatment for moderate to severe IDA [14].
Iron Sucrose and Ferric Carboxymaltose are dextran free
intravenous iron alternatives. When compared to oral iron
in pregnancy iron sucrose is superior with respect to the
rate of both haemoglobin increase and iron store replen-
ishment, combined with a good safety profile [12,15,16].
Serious adverse effects are rare with iron sucrose, however
minor side effects occur in up to 18% of patients which
may in part be attributed to its non-physiological physical
properties (high pH and high osmolarity). Ferric carboxy-
maltose is a newer dextran-free iron formulation with a
near neutral pH, physiological osmolarity and increased
bioavailability which allows for single dose, short 15 minute
infusion time and higher dosing (up to 1000 mg) [17].
These properties make ferric carboxymaltose an attractive
alternative to iron sucrose in terms of risk profile, efficacy,
patient comfort and convenience, staff and institutional
resource utilization.
To date, there are few clinical studies using ferric car-
boxymaltose in pregnant women. The primary aim ofthis study was to assess the use of intravenous ferric car-
boxymaltose in the correction of iron deficiency anaemia
in pregnant women. The secondary aims were to deter-
mine the extent and severity of adverse effects of ferric
carboxymaltose, and to evaluate the perceived quality of
life of women in the post-partum period.
Methods
After approval by the Queen Elizabeth Hospital, Lyell
McEwin Hospital & Modbury Hospital Human Research
and Ethics committee (Reference number 2011160) this
prospective study was performed between July 2011 and
September 2012. Informed consent was waived by the
ethics committee for data collection, as ferric carboxy-
maltose was being used as our routine clinical treatment
modality in this setting.
Pregnant women with documented IDA, defined as
Hb < 115 g/dl, who consecutively presented as outpa-
tients in the Women’s Assessment Unit at the Lyell
McEwen Hospital (Elizabeth Vale South Australia) to re-
ceive ferric carboxymaltose infusions were recruited to
this study. A total of 65 women were included. Due to
the limited availability of safety data for its use in preg-
nancy, we adopted a longer infusion protocol (30 min)
than recommended by the manufacturer (15 min). Ma-
ternal blood pressure was taken every five minutes dur-
ing infusion and foetal heart rate was assessed before
and after infusion. According to routine antenatal care
blood samples were collected to measure haemoglobin,
and in some cases ferritin levels, prior to infusion and
then again, where clinically indicated, at up to three
post-infusion visits (at approximately 3, 6 and 8 weeks).
Haemoglobin and ferritin concentrations were deter-
mined in the hospital laboratory using Sodium lauryl
sulphate (SLS) method for Hb analysis (Sysmex XE2100
analyser) and direct chemiluminometric sandwich im-
munoassay (Siemens ADVIA Centaur XP) for ferritin
analysis. Women were observed for one hour post infu-
sion, before being discharged home. Medical and path-
ology data were collated from case notes and electronic
laboratory reports, as well as transfusion data linkage re-
ports. A telephone interview was conducted after all 65
patients delivered to evaluate well-being after the infu-
sion. Patients were asked to place themselves into 1 of 4
allocated categories (worse, no different, better or much
better), which reflected degrees of perceived change in
symptomatology since infusion.
The data were analysed using Graph Pad Prism 5,
using p values of ≤0.05 to indicate significance. Available
pre-infusion, post-infusion and post-partum haemoglo-
bin, ferritin and transferrin saturation levels were com-
pared using one-way ANOVA tests. Tukey’s multiple
comparison tests were used to assess changes in
levels across the time points measured with Dunn’s
Figure 1 Mean ± SEM haemoglobin levels (g/L). *p < 0.01
compared to baseline (pre-infusion), #p < 0.01 compared to 3 weeks.
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when necessary.
Results
The characteristics of the women receiving ferric car-
boxymaltose for iron deficiency anaemia are outlined in
Table 1. A total of 65 women received a ferric carboxy-
maltose infusion for antenatal iron deficiency anaemia,
with pre-infusion haemoglobin data available for all 65
women. Following infusion, haemoglobin values were re-
peated by the obstetric team as required and data were
available for 88% of women: 31 women (48%) at visit 1
(3 weeks post infusion), 26 women (40%) at visit 2
(6 weeks post infusion) and a total of 20 (31%) women
had a blood test at visit 3 (8 weeks post infusion; post-
partum). All women responded to the treatment with in-
creased Hb values.
Of the 65 women entered into the study, 18 (27.7%)
women were defined as having severe anaemia (Hb <90
g/dl), while 12 women (18.5%) were defined as having
moderate anaemia (90–94 g/dl) and the remaining 35
(55.8%) women had mild anaemia (95–116 g/dl)
Changes in haemoglobin concentration over the post-
infusion period are presented in Figure 1. The pre-
infusion haemoglobin level was significantly lower than
haemoglobin values measured at all subsequent visits
(p < 0.01 in each case). There was a significant increase
in haemoglobin levels from 3 to 6 weeks post-infusion
(average increase 12 g/dl; p < 0.01). By 8 weeks post-
infusion, these values had returned back to levels com-
parable with those observed at 3 weeks post-infusion,
which were still significantly higher than pre-infusionTable 1 Demographic information of women in the study
Age (years) 28.3 ± 7.3
BMI 28.3 ± 8.2
Gravidity 4 ± 3
Parity 2 ± 2
Mode of delivery
Vaginal 38 (58.4%)
Elective Caesarean 19 (29.2%)
Emergency Caesarean 4 (6.2%)
Instrumental 4 (6.2%)
Oral iron supplements 31 (48%)
Iron intolerance 10 (15%)
Blood loss (ml) 413 ± 340
Gestational age at intervention (weeks) 34.3 ± 3.6
Haemoglobin at booking (12 weeks) 113.4 g/L
Ferritin at booking (12 weeks) 17 μg/L
Data are presented as n (%) or mean (± standard deviation).levels. When IDA severity was included in the analysis, a
similar pattern of results emerged (Table 2). For all three
severity groups, haemoglobin levels increased post infu-
sion at 3 and 6 weeks, to be significantly higher than
baseline levels (p < 0.01 in all cases). However, the post-
partum haemoglobin levels were only significantly higher
than baseline in the women with mild IDA (p < 0.01),
while haemoglobin levels in the moderate and severe
groups had reverted back to pre-infusion levels. The
analysis of the post-partum haemoglobin levels, however,
was limited by small numbers in each group at this time
point (mild n = 11, moderate n = 3, severe n = 4).
Ferritin values increased significantly after the infusion
(Table 3). As there was no strict protocol, post-partum
ferritin levels were available for only 2 patients. How-
ever, despite the limitation, these values indicate reason-
ably replenished iron stores, with mean (±SD) levels of
151 μg/L (± 4.2).
All adverse reactions are presented in Table 4. No ser-
ious adverse effects were recorded in any of the 65 women
receiving an infusion. Minor side effects occurred in 13
(20%) patients. One patient required medication with
Metoclopramide for nausea and vomiting. All other ad-
verse events were self-limiting. Fetal heart rate monitoring
did not indicate a drug related adverse effect on the fetal
heart pattern. Red blood cell transfusions were required
by 3 women (4.6%) in the study cohort, all of whom had a
significant peri-partum haemorrhage.
Follow-up interview by telephone was conducted on
29 (44.6%) women in the post-partum period. Of these
women, 19 (65.5%) reported an improvement in their
wellbeing (48.3% reported feeling “much better”, 17.2%
reported “a little better”, and 9 (31%) reported feeling
“no different”) after the infusion. One woman was un-
willing to provide information. None of the women re-
ported feeling worse.
Table 2 Haemoglobin levels (g/L) across the testing period for women in the study, split by severity of iron deficiency
anaemia at study enrolment
Gestational age at entry Pre-infusion 3 weeks post infusion 6 weeks post infusion 8 weeks post infusion
(post-partum)
Mild ≥95 g/L 34 (4) 102.1 (1.0) n = 31 108.3 (3.9)* n = 28 120.6 (2.9)* n = 18 113.1 (4.2)* n = 11
Moderate 90-94 g/L 36 (2) 92.6 (0.4) n = 14 105.8 (3.0)* n = 13 108.4 (3.8)* n = 5 92.7 (12.4) n = 3
Severe <90 g/L 34 (3) 83.7 (0.9) 20 100.2 (3.3)* n = 17 110.0 (8.1)* n = 5 93.3 (8.1) n = 4
Data are presented as means (SEM). *p < 0.01 compared to pre-infusion haemoglobin levels.
Table 4 Number of women experiencing a drug related
adverse events following infusion with ferric
carboxymaltose (total number of women infused n = 65)
Adverse event n (%)
Any adverse event 13 (20)
Local (injection site irritation)
Slight burning sensation 5 (8)
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This is the first prospective study reporting on ferric car-
boxymaltose infusions in pregnancy. The key finding of
our study is that in women presenting with IDA rela-
tively late in pregnancy, a ferric carboxymaltose infusion
prior to delivery significantly increased haemoglobin
levels and improved iron stores. Further, we demonstrate
that ferric carboxymaltose appears to be a safe and ef-
fective treatment modality for the correction of IDA, as
no serious adverse events and only few minor adverse
events reported. Reassuringly, patient satisfaction rating
and improvement in perceived wellbeing assessed in the
postnatal period was high
Many women develop iron deficiency during pregnancy,
a condition that can have serious maternal and fetal impli-
cations [14]. In our cohort, first trimester booking bloods
showed only discrete anaemia with mean Hb of 113.4 g/L,
but all women studied developed moderate to severe IDA.
The low mean ferritin at booking of 17 μg/L represent pro-
found iron deficiency and reiterates the importance of fer-
ritin as a screening tool. This finding should generally
result in the initiation of iron supplementation. For some
women oral iron supplementation appears to be sufficient
to maintain adequate iron stores. However many women
develop moderate to severe IDA despite oral iron supple-
mentation (as demonstrated in the current study where
48% of women were on oral iron), or due to drug into-
lerance (15% in the current study), non-adherence or
pre-disposing pathology such as malabsorption or inflam-
matory bowel disorders. For those women intravenous iron
administration may be a more effective treatment modality.
To date no prospective, controlled clinical study has
been performed using ferric carboxymaltose in pregnant
women. A recent Cochrane review concluded that large,
good quality trials, assessing clinical outcomes (including
adverse effects) as well as the effects of treatment by se-
verity of anaemia are required [18]. In the absence of
these studies, observational safety and efficacy data may
help identify potential benefits and risks. Two recentTable 3 Ferritin levels (μg/L) across the testing period for
women in the study
Booking Pre infusion Post infusion
Ferritin μg/L 13.5 (13) n = 47 6.5 (3.9) n = 25 194 (316)* n = 24
Data are presented as means (SD). *p < 0.05 compared to pre-infusion levels.retrospective observational studies comparing ferric car-
boxymaltose to different intravenous iron preparations
highlighted the safety and efficacy of ferric carboxymal-
tose [19,20].
The rapid delivery option of a large single dose of fer-
ric carboxymaltose offers a promising treatment modal-
ity for pregnant women who need correction of iron
deficiency and anaemia, over other IV iron formulations
that have low dosage limits, such as iron sucrose
(200 mg). The properties of ferric carboxymaltose may
also reduce the burden on the patient and the health
care system.
In obstetrics, red blood cell transfusions currently ac-
count for 3–4% of all transfusion events and the major-
ity of these occur following post-partum haemorrhage
(PPH) [21]. PPH is the leading cause of maternal mortal-
ity in obstetrics, and is estimated to occur at a rate of
13.1% [9]. Despite its enormous clinical utility, RBC
transfusion is a treatment with well described adverse
events and risk, and should ideally be avoided. Addition-
ally blood is both costly and in ever increasingly short
supply [22-24]. In the present cohort, only three patients
(4.6%) required a RBC transfusion following a significant
PPH. A recent large retrospective study revealed much
higher transfusion rates of 7.5% in women with clinical
PPH [25]. The current data suggests that improving Hb,
even at a late stage of the third trimester may have
shielded some mothers in our cohort from the risks of
an allogeneic transfusion. This does not only spare re-
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ging post-partum period [4,26].
Conclusion
The data from this prospective case series is consistent
with existing retrospective data that ferric carboxymal-
tose administration in the second and third trimester of
pregnancy is likely to be safe and effective. In our study
ferric carboxymaltose successfully corrected IDA prior
to delivery. The intervention prevented significant post-
partum anaemia in all women resulting in post-partum
haemoglobin values higher than their pre-treatment
antenatal values. Despite moderate to severe anaemia at
presentation, labour associated blood loss was tolerated
well resulting in low peri-partum RBC transfusion rates.
No serious adverse events were recorded. Well-being
also improved for the majority of women after the
infusion.
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